Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx zahraničních věcí,

kterým xx xxxx a xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx zahraničních xxxx sděluje, že xxx 1. xxxxx 2023 xxxx generální xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx nového xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x metod xxxxxxx xxx xxx 2024 - Mezinárodní xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve xxxxxx.

X xxxxx zněním Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx listinu x xxxxxxx změn Xxxxxxx X Českou xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x souladu x článkem 34 odst. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx republiku xxxxxxxxx x xxxxxxxx xxx 18. června 2024 x xxxxxxxxx Přílohu X xxx xxx 2023, platnou od 1. ledna 2023, xxxxx xxxxxxxxx x xxxxxxxx xxx Českou xxxxxxxxx dne 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X xxx xxx 2024 x xxxx xxxxxxx do xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. XXXx. Xxxxxx, Xx.X., XX.X., x. r.

vrchní xxxxxxx xxxxx právní x xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Překlad xxxxxxxxxxx smlouvy xx xxxxxxx xxxxxx

Xxxx

Xxxxxx xxxxxxxxxx xxxxx a metod xxxxxxx xx povinný Xxxxxxxxxxx standard x xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx xx každoročně xxxxxxxxxxxx po xxxxxxxxx xxxxxxxxxxxx procesu xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Xxxxxx xx xxxxxx od 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxx xxxxxxxxx XXXX x xxxx xxxxxxxxxx v xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx anglickým x xxxxxxxxxxxx xxxxxx xxxxxxxxx znění x xxxxxxxxxx.

Xxxx xxxx uvedeny xxxxxxx xxxxx xxxxxxxxx x tomto Xxxxxxx xxxxxxxxxx látek a xxxxx.

Xxxxxxxx Xxx xxxxxxx

Xxxxx XXXX pro xxxx xxxxx neschválila xxxx xxxxxx, xx xxxxxx Xxx xxxxxxx x xxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxx xxxxxxx (xx 23:59 xxxxx) x den xxxxxxxxxxxxx Xxxxxxx, které se xx Xxxxxxxxx xxxxxxxxx, xx xx xxxxx Xxxxxxx x xxxxxxx xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, že xxxx xxxxx nebo xxxxxx xx zakázána Xxx xxxxxxx x Mimo xxxxxx, xxx je xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 xxxxx všechny Xxxxxxxx xxxxx Specifickými xxxxxxx, x xxxxxxxx těch xxxxxxxxxx x Xxxxxxx xxxxxxxxxx xxxxx a xxxxx dopingu. Xxxxx Xxxxxxxx xxxxxx nebude Xxxxxxxxxxx xxxxxxx, xxxxx xxxx v Seznamu xxxxxxxxx xxxxxxxx jako Xxxxxxxxxx metoda.“ Podle xxxxxxxxx x xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx metody xxxxxxx x xxxxxx 4.2.2 xx xxxxxx být xxxxxx xxxxxxxx xxxxxxxxxx xx méně xxxxxxxx xxxx xxxx xxxxxxxxxx xxx jiné dopingové xxxxx xxxx metody. Xxx spíše x xxxxx x xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx xxxxx xxx xx xxxxxxxx xxxxxxxxxxx xxxxxx.“

Xxxxxxxx xxxxx

Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx látky, xxxxx xxxx xxxx xxxxxx xxxxxxxx z xxxxxx xxxxxx xxxxxxx xxxxxxxxxx ve xxxxxxxxxxx xxxx xxxxx sportu. Xxxx Xxxxxxxx látky xxxx xxxxxxxxxx tyto xxxxx: xxxxxx, diamorfin (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 XXXXXXXXXXX XXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx zakázané xxxxx x této xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx se nevztahuje xxxxx x následujících xxxxxx Seznamu x xxxxx xxxx x xxxxxxxx době xxxxxxxxx xxxxxx vládním xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx u xxxx (xxxx. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx vývoji xxxx xxxxxxx xxxxx byl xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx použití), xx zakázána stále.

Tato xxxxx zahrnuje xxxxx xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x aktivátory xxxxxxxxx (např. Reldesemtiv x Xxxxxxxxxx).

X1 ANABOLICKÉ XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxx xxxxx jsou xxxxxxxx.

X1.1. XXXXXXXXXX XXXXXXXXXX STEROIDY (XXX)

Xxx exogenním xxxxxx, xxxx xxxx včetně:

•	1-androstenediol (5ɑ-xxxxxxx-1-xx-3ß, 17ß-diol)		•	formebolon
•	1-androstenedion (5ɑ-xxxxxxx-1-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-hydroxy-5a-androst-1-en-17-on)		•	gestrinon
•	1-epiandrosteron (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on)		•	mesterolon
•	4-androstenediol (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on)
•	4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on)		•	metenolon
•	5-androstenedion (xxxxxxx-5-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		&xxxx;•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on)
•	7-keto-DHEA		•	metylklostebol
•	11ß-metyl-19-nortestosteron		•	metyldienolon (17β-hydroxy-17α-metylestra-4,9-dien-3-on)
•	17ɑ-methylepithiostanol (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx)
•	19-xxxxxxxxxxxxxxxxx (estr-4-en-3,17-diol)		•	metyltestosteron
•	19-norandrostenedion (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (metyltrienolon, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxx (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (androsta-1,4-dien-3,17-dion)		•	oxandrolon
•	calusteron		•	oxymesteron
•	klostebol		•	oxymetolon
•	danazol ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (dehydroepiandrosteron, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)		&xxxx;•	xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)		&xxxx;•	xxxxxxxxxxx
•	xxx-xxxxxxxxxxxxxxxxxx (17β-hydroxy-5β-androstan-3-on)		•	tetrahydrogestrinon (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-norpregna-4-en-17α-ol)		•	trenbolon (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT)

a xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X1.2. XXXXXXX XXXXXXXXXX LÁTKY

Mimo xxxx xxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], zeranol a xxxxxxxxxx.

X2 XXXXXXXXX XXXXXXX, XXXXXXX FAKTORY, XXXXXXXX XXXXX A XXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxx x další látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky jsou xxxxxxxx.

X2.1. XXXXXXXXXXXXX (XXX) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx jiné xxxxxx:

X2.1.1 Xxxxxxxx erytropoetinových receptorů, xxxx. xxxxxxxxxxxx (dEPO); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx EPO, [xxxx. EPO-Fc, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx prostředky a xxxxxx sloučeniny, xxxx. XXXX-530, peginesatid.

S2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.

X2.1.4 Inhibitory xxxxxxxxxxx xxxxxxxxxxxxxxxx růstového xxxxxxx xxxx (TGF-β), xxxx. xxxxxxxxxxxx; sotatercept.

S2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx receptoru, xxxx. xxxxxx XXX; xxxxxxxxxxxxx EPO (XXXX).

X2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1 Xxxxxxx xxxxxxxxxxx testosteron x mužů, xxxx xxxx xxxxxx:

• xxxxxxxx xxxxxxxxxxxx (CG),

• xxxxxxxxxxxx xxxxxx (LH),

• xxxxxx xxxxxxxxxx gonadotropin (GnRH, xxxxxxxxxxx) x xxxx xxxxxxxxxxx analogy (např. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, nafarelin x triptorelin),

 • xxxxxxxxxx x xxxx xxxxxxxxxxx xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. kortikorelin x xxxxxxxxxxxxx.

X2.2.3 Růstový xxxxxx (XX), xxxx xxxxxxx x xxxxxxxxx, mimo xxxx xxxxxx:

• xxxxxxx xxxxxxxxx hormonu, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx a xxxxxxxxxx,

• fragmenty xxxxxxxxx xxxxxxx, např. AOD-9604 x xXX 176–191.

X2.2.4 Xxxxxxx uvolňující xxxxxxx xxxxxx, xxxx xxxx xxxxxx:

• xxxxxx uvolňující xxxxxxx xxxxxx (GHRH) x jeho xxxxxxx, xxxx. CJC-1293, XXX-1295, xxxxxxxxxx x tesamorelin,

• xxxxxxxxxxx růstového xxxxxxx (XXX) x xxxxxx xxxxxxxx [např. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, xxxxxxxxxxx (ghrelin), xxxxxxxxxxx a tabimorelin],

• xxxxxxx uvolňující XX (XXXX) [např. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (pralmorelin), GHRP-3, XXXX-4, XXXX-5 x XXXX-6].

X2.3. XXXXXXX XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx jiné xxxxxx:

• xxxxxxxxxxxxx xxxxxxx faktory (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (HGF)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (IGF-1, xxxxxxxxxx) x jeho xxxxxxx

• xxxxxxxxxx růstové faktory (XXX)

• xxxxxxx xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX)

• xxxxxxxx-β4 x xxxx xxxxxxxx, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX)

x xxxxx xxxxxxx faktory xxxx xxxxxxxxxx růstových xxxxxxx xxxxxxxxxxx syntézu/degradaci xxxxxxxx xx xxxxxxx, xxxxxxxx nebo vazech, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx xxxx svalových xxxxxx.

X3 BETA-2 XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky v xxxx xxxxx xxxx Xxxxxxxxxx látky.

Všichni xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 xxxxxxxx včetně všech xxxxxxxxx izomerů xxxx xxxxxxxx.

Xxxx jiné včetně:

•	arformoterol		•	indakaterol		•	reproterol		•	tretoquinol (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Inhalační xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx dávkách, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 hodin xx xxxxxxxxx xxxxx;

• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 xxxxxxxxxx xx 24 hodin.

POZNÁMKA

Přítomnost salbutamolu x moči x xxxxxxxx vyšším xxx 1000 xx/xx xxxx xxxxxxxxxxx v xxxxxxxx xxxxxx xxx 40 xx/xx neodpovídá xxxxxxxxxxxxxx xxxxxxx látky x xxxx považována xx Xxxxxxxxx laboratorní nález (XXX), pokud Sportovec xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxxx xxxxxxxxxxxx dávky (xxxxxxxxx) xx do xxxx xxxxxxx xxxxxxxxx xxxxx.

X4 XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxxx xxxxx xx xxxxxxx X4.1 a X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx xxxxxxxx do xxxx S4.3 a X4.4 xxxx Nespecifické xxxxx.

Xxxxxxxxxxx hormonové a xxxxxxxxxxx modulátory jsou xxxxxxxx.

X4.1. XXXXXXXXXX AROMATÁZ

Mimo xxxx xxxxxx:

•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-3,5-xxxx-7,17-xxxx (arimistan)
•	3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	4-xxxxxxxxx-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX ESTROGENOVÝCH RECEPTORŮ (XXXXX)]

Xxxx xxxx včetně:

•	arformoterol		•	indakaterol		•	reproterol		•	tretoquinol (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX RECEPTORU XXXXXXXX XXX

Xxxx jiné včetně:

•	protilátky xxxxxxxxxxxxxx xxxxxxx X		•	xxxxxxxxxx xxxxxxxxxx, xxxx.:
•	xxxxxxxxxx receptoru xxxxxxxx XXX, xxxx.:			- xxxxx xxxxxxxxx xxxx xxxxxx xxxxxxx xxxxxxxxxx
	- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031)			- proteiny xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx myostatinu)
•	protilátky xxxxx xxxxxxxxx aktivinu XXX (xxxx. xxxxxxxxxx)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx prekurzory (např. xxxxxxxxxxx, domagro xxxxx, xxxxxxxxxxxxx, stamulumab)

S4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), např. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx (PPARδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (trifluormetyl)fenyl)thiazol-5-yl)metylthio)fenoxy) kyselina xxxxxx (GW1516, XX501516) x agonisté Xxx-xxxɑ , xxxx. XX9009, XX9011

X4.4.2 xxxxxxxx a xxxxxxxx xxxxxxxx

X4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 DIURETIKA A XXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX I XXXX SOUTĚŽ)

Všechny zakázané xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx, včetně xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxx xxxx včetně:

•  Diuretika, xxxx např.:

acetazolamid; amilorid; xxxxxxxxx; xxxxxxxx; chlortalidon; xxxxxxxx xxxxxxxxxx; furosemid; xxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; triamteren;

• Xxxxxxx, xxxx. konivaptan, mozavaptan, xxxxxxxxx;

• Xxxxxxxxxxx expandéry xxxxxxxx xxxxxxxxxxxx, např.:

albumin, xxxxxxx, xxxxxxxxxxx škrob, xxxxxxxx;

• Desmopresin;

• Xxxxxxxxxx;

x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými biologickými xxxxxx.

XXXXXXX

• xxxxxxxxxxx; pamabrom; x lokální oftalmologické xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. dorzolamid, brinzolamid);

• xxxxxxx xxxxxx xxxxxxxxxxx x zubní xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx prahovým xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx a pseudoefedrinu xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxx případně Xxx Soutěži xx xxxxxxx x diuretikem xxxx xxxxx maskovací xxxxxx (xxxxx xxxxxxxxx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx nebo lokálního xxxxxx xxxxxxxxxxx v xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález (XXX), xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Terapeutickou xxxxxxx (XX) xx tuto xxxxx navíc k xx, xxxxx již xxxx xxxxxxx xx xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx s xxxxxxxx xxxxx x X2.2, xxx jsou Xxxxxxxxxx xxxxxx.

X1. MANIPULACE S XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

X1.1. Xxxxxx xxxx opětovné xxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx produktů x xxxxxxxxx krvinek jakéhokoliv xxxxxx xx oběhového xxxxxxx s xxxxxxxx xxxxxxxx plazmy xxxx xxxxxx složek Sportovci xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x registrovaném xxxxxxxxx xxxxxx.

X1.2. Xxxxx zvyšování xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; efaproxiral (RSR13); xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xx xxxx xxxxxxxxxxx a xxxxxxxxxxxxxxxx hemoglobinové xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx manipulace x xxxx xxxx x xxxxxxxx komponentami xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Xxxxxxxxx nebo Xxxxx x podvod xx xxxxxx xxxxxxx xxxxxxxxx x platnost Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx kontrole.

Mimo jiné xxxxxx:

Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. přidáním xxxxxxx xx Xxxxxx.

X2.2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx více než xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxxx, chirurgických xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx vyšetření.

M3. XXXXXX X XXXXXXX XXXXXX

X xxxxxx potencionálního zvýšení xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

X3.1. Použití xxxxxxxxxx xxxxxxx xxxx xxxxxx analogů, xxxxx xxxxx změnit xxxxxxxx xxxxxx a/nebo xxxxxxx xxxx jakýmkoliv xxxxxxxxxxx. Xx xxxx jiné xxxxxxxx technologie xxxxx xxxx, xxxxxxxxx genů x xxxxxxxxxxx xxxxxxx xxxx.

X3.2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 STIMULANCIA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx látky x výjimkou látek xxxxxxxxx x S6.A, xxx jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxx látky x xxxx xxxxx: kokain x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)

Všechna xxxxxxxxxxx, xxxxxx všech xxxxxxxxx izomerů, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxxxxxxxxx zahrnují:

S6.A: XXXXXXXXXXXX XXXXXXXXXXX

•	xxxxxxxxx		•	xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx není xxxxxxxx xxxxxx v xxxxx oddíle, xx Xxxxxxxxxxx látkou.

S6.B: XXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin)		•	hydrafinil (xxxxxxxxx)		•	xxxxxxxxxxx x xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxx1)		•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxx a xxxx xxxxxxx, xxxx. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (dimetylamfetamin)		•	metylendioxymetamfetamin		•	selegilin
•	efedrin3)		•	metylefedrin3)		•	sibutramin
•	epinefrin (adrenalin)4)		•	metylnaftidát [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx v xxxxxxx jejich xxxxxxx, xxxxxxx, xxxxxx xxxx xxxxxx xxxxxxx (např. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xylometazolin) x xxxxxxxxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx v xxxx xxxxx: diamorfin (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x l, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx a jeho xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (heroin)		•	metadon		•	oxykodon		•	tramadol
						•	oxymorfon

S8 KANABINOIDY

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx zakázané xxxxx v xxxx xxxxx jsou Xxxxxxxxxx xxxxx. Návykové látky x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x syntetické xxxxxxxxxxx xxxx xxxxxxxx, xxxx.

• x konopí (xxxxx, xxxxxxxxx) a xxxxxxxxx xxxxxxxxxx

• xxxxxxxx x xxxxxxxxxx tetrahydrokanabionoly (THC)

• xxxxxxxxxx kanabinoidy napodobující xxxxxx XXX

XXXXXXX

• kanabidiol

S9 XXXXXXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx v xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx glukokortikoidy xxxx xxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [včetně xxxxxxxxxx (např. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Xxxx xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, intranazálního, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) nejsou zakázány, xxxxx xx xxxxxxxxx x rámci výrobcem xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxx.

X1 BETA-BLOKÁTORY

ZAKÁZANÉ X XXXXXXXX SPORTECH

Všechny xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx v xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx x kde xx xx označeno xxxxxxxx (*) x Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• lyžování/snowboarding (XXX) – xxxxx xx xxxxxx, akrobatické xxxxx / X-xxxxx x xxxxxxxxx X-xxxxx / xxx air

• automobilový xxxxx (XXX)

• podvodní xxxxxx (XXXX)* x xxxxxxxxxxxx volného xxxxxxxx, xxxx harpunou a xxxxxxx na terč

• xxxxxxxx (všechny xxxxxxxxxx) (XXXX)

• šipky (XXX)

• xxxx (IGF)

• xxxxxxxx (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx xxxx Xxxx xxxxxx

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Znění xxxxxxxxxxx smlouvy x xxxxxxxxx jazyce
 

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: je xxxxxxxx xxxxx xxx koncentraci x xxxx vyšší xxx 5 xxxxxxxxxx x 1 ml.

²⁾ xxxxxxxxxxxxx: xxxxxxxx pouze xxx xxxxxxxxxxx x xxxx xxxxx xxx 150 mikrogramů v 1 xx.

³⁾ xxxxxxx x xxxxxxxxxxxx: zakázány xxx xxxxxxxxxxx x xxxx xxxxx xxx 10 xxxxxxxxxx v 1 xx.

⁴⁾ epinefrin (xxxxxxxxx): není xxxxxxxx xxxxxxx podávání, xxxx. xxxxx, xxxx, xxxx xxxxxxxx podávání s xxxxxxxxx xxxxxxxxxx.

⁵⁾ bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, pipradrol x xxxxxxxx: xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2024 x xxxxxx považovány xx Zakázané xxxxx.

Informace

Právní xxxxxxx x. 19/2025 Sb. nabyl xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx právních předpisů x odkazech není xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx